Wed, Apr 16, 2014, 7:55 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Amylin Pharmaceuticals, Inc. Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • fudfighter4 fudfighter4 May 28, 2012 6:40 AM Flag

    The various cancer risks associated with exenatide therapy

    Does anybody here see the Public Citizens' initiative as being a factor in any buyout valuation of Amylin?

    Many posters here seemed to be optimistic that Public Citizens might be able to leverage their finding of an increased rate of thyroid cancer in diabetics who took Victoza to force the FDA to withdraw approval of the main competitor to exenatide therapy.

    But the search also discovered a rate of thyroid cancer in diabetics who took Byetta which seemed to be proportionate to its use - and the conclusion was that an increased risk of thyroid cancer was common to GLP-1 therapy, as no cases were discovered in diabetics who took Januvia.

    Surely anybody contemplating making an offer to buy the Company must be aware of the possibility of an FDA withdrawal of Byetta and Bydureon - and must be wondering if there are far safer biotech acquisitions available on which to spend $6 billion or more?

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • I'm guessing that this individual has lost interest in our discussion. Does anybody else here have any thoughts on the buyer perception of the risk that the FDA could withdraw approval of Byetta and Bydureon on the grounds of protecting public health?

      After all, there are other competitive therapies - Januvia for one - which don't seem to carry the same risk of thyroid cancer.

 

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.